Noninvasive serologic biomarkers for liver fibrosis

[Guest guest]

Noninvasive serologic biomarkers for liver fibrosis

Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI

,

The gold standard of assessing liver fibrosis is liver biopsy, which is invasive and not without risk. Therefore, searching for noninvasive serologic biomarkers for liver fibrosis is an importantly clinical issue.

,

Methods:

,

A total of 16 healthy volunteers and 45 patients with chronic hepatitis C virus (HCV) were enrolled (F0: n=16, F1: n=7, F2: n=17, F3: n=8 and F4: n=13, according to the METAVIR classification).Three serum samples of each fibrotic stage were analyzed by two-dimension difference gel electrophoresis (2D-DIGE). The differential proteins were identified by the cooperation of MALDI-TOF/TOF and MASCOT; then western blotting and Bio-Plex Suspension Array were used to quantify the protein levels.

l

Results: Three prominent candidate biomarkers were identified: alpha 2 macroglobulin (A2M) is up regulated; vitamin D binding protein (VDBP) and apolipoprotein AI (ApoAI) are down regulated.The serum concentration of A2M was significantly different among normal, mild (F1/F2) and advanced fibrosis (F3/F4) (p less then 0.01).> ,

Conclusions: This study not only reveals three putative biomarkers of liver fibrosis (A2M, VDBP and ApoAI) but also proves the differential expressions of those markers in different stages of fibrosis.We expect that combination of these novel biomarkers could be applied clinically to predict the stage of liver fibrosis without the need of liver biopsy.Author: Ai-Sheng HoChun-Chia ChengShui-Cheng LeeMeng-Lun LiuJing-Ying LeeWen-Ming WangChia-Chi WangCredits/Source: Journal of Biomedical Science 2010, 17:58

http://Hepatitis Cnewdrugs.blogspot.com/2010/07/noninvasive-serologic-biomarkers-for.html

[Guest guest]

Great article Don, you know I have always worried about this test. I asked my gastro point blake why he wouldnt do a biopsy he said a biopsy wasnt neccesary that the firborsure test told him all he need to know. Makes me feel better about it and his decission. I think he is really smart, not much on the bedside manner. Thanks again for the article~~

From: Christ <ludichrist2000@...>Subject: [ ] Noninvasive serologic biomarkers for liver fibrosis"009 - VCHepC" <VCHepC >, "Hepatitis C" <Hepatitis C >, "WebWarriors grp" < >Date: Friday, July 16, 2010, 5:36 PM

Noninvasive serologic biomarkers for liver fibrosis

Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI

,

The gold standard of assessing liver fibrosis is liver biopsy, which is invasive and not without risk. Therefore, searching for noninvasive serologic biomarkers for liver fibrosis is an importantly clinical issue.

,

Methods:

,

A total of 16 healthy volunteers and 45 patients with chronic hepatitis C virus (HCV) were enrolled (F0: n=16, F1: n=7, F2: n=17, F3: n=8 and F4: n=13, according to the METAVIR classification) .Three serum samples of each fibrotic stage were analyzed by two-dimension difference gel electrophoresis (2D-DIGE). The differential proteins were identified by the cooperation of MALDI-TOF/TOF and MASCOT; then western blotting and Bio-Plex Suspension Array were used to quantify the protein levels.

l

Results: Three prominent candidate biomarkers were identified: alpha 2 macroglobulin (A2M) is up regulated; vitamin D binding protein (VDBP) and apolipoprotein AI (ApoAI) are down regulated.The serum concentration of A2M was significantly different among normal, mild (F1/F2) and advanced fibrosis (F3/F4) (p less then 0.01).> ,

Conclusions: This study not only reveals three putative biomarkers of liver fibrosis (A2M, VDBP and ApoAI) but also proves the differential expressions of those markers in different stages of fibrosis.We expect that combination of these novel biomarkers could be applied clinically to predict the stage of liver fibrosis without the need of liver biopsy.Author: Ai-Sheng HoChun-Chia ChengShui-Cheng LeeMeng-Lun LiuJing-Ying LeeWen-Ming WangChia-Chi WangCredits/ Source: Journal of Biomedical Science 2010, 17:58

http://Hepatitis Cne wdrugs.blogspot. com/2010/ 07/noninvasive- serologic- biomarkers- for.html